FASN and cancer: Importantly, both aberrant lipolysis and increased lipogenesis have been identified in many BCL subtypes, including mantle cell lymphoma and chronic lymphocytic leukemia.[5] Elevated levels of fatty acid synthase (FASN) have been reported in double‐expressor lymphoma.[6] Changes in other lipid components, such as increased cholesterol[7] and cardiolipin,[8] promote lymphomagenesis and are potential therapeutic targets for cancer treatment.